Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Mum On Lipitor Plans, Advises Patience Until Nov. 30, When “Reality” Will Emerge

This article was originally published in The Pink Sheet Daily

Executive Summary

On a quarterly earnings call, Ranbaxy management seemed upbeat about their ability to come to terms with US regulators in a timely manner, but they hedged on specifics.


Related Content

Ranbaxy's Anti-Malarial Approval Makes It First Indian Firm To Fully Develop An NCE
Ranbaxy Woes Continue With 30-plus Product Import Alert


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts